A clinical trial for INKmune immune therapy, focused on metastatic castration-resistant prostate cancer, expanded to include veterans at the West Los Angeles VA Medical Center.
The therapy seeks to enhance natural killer cells’ tumor-fighting ability, offering an outpatient option with promising safety and efficacy. A very promising new approach! The trial started recruitment in Feb 2024.
OVM-200 Phase 1 clinical trial ( vaccine)
New Mitochondrial enzyme target, and a chance for Oligometastatic patients to step up--MetaCure trial-some information